#1 Clinical Trials Search in Europe

Avatrombopag

Avatrombopag is an oral thrombopoietin receptor agonist that has shown promise in treating various conditions associated with low platelet counts. This article explores the use of avatrombopag in clinical trials for conditions such as severe aplastic anemia, immune thrombocytopenia, and chemotherapy-induced thrombocytopenia. We’ll examine its efficacy, safety, and potential benefits for patients with these challenging blood disorders.

Table of Contents

What is Avatrombopag?

Avatrombopag is a medication used to treat various conditions related to low platelet counts in the blood. It is also known by the brand name Doptelet[5]. Avatrombopag belongs to a class of drugs called thrombopoietin receptor agonists (TPO-RAs), which help stimulate the production of platelets in the body[2].

How Does Avatrombopag Work?

Avatrombopag works by mimicking the effects of a natural hormone called thrombopoietin (TPO) in the body. TPO is responsible for stimulating the production of platelets, which are essential for blood clotting. By activating the TPO receptors, avatrombopag helps increase the number of platelets in the blood, which can be beneficial for patients with various conditions causing low platelet counts[2].

Conditions Treated with Avatrombopag

Avatrombopag is used to treat several conditions characterized by low platelet counts (thrombocytopenia). These include:

  • Chronic liver disease: Avatrombopag is used to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or surgical procedure[7].
  • Immune thrombocytopenia (ITP): This is an autoimmune disorder where the immune system mistakenly attacks and destroys platelets. Avatrombopag is used to treat both adult and pediatric patients with ITP[5][9].
  • Aplastic anemia: This is a rare but serious condition where the bone marrow fails to produce enough blood cells, including platelets. Avatrombopag is being studied for use in patients with severe aplastic anemia[1][6].
  • Cancer-related thrombocytopenia: Avatrombopag is being investigated for use in cancer patients who develop low platelet counts due to chemotherapy or liver disease[2][4].
  • Thrombocytopenia in hepatocellular carcinoma (HCC): Avatrombopag is being studied for use in patients with liver cancer (HCC) who have low platelet counts and need to undergo certain procedures[10].

Dosage and Administration

Avatrombopag is typically taken orally in tablet form. The dosage and duration of treatment can vary depending on the specific condition being treated and the patient’s individual needs. Some general guidelines include:

  • For chronic liver disease: 40-60 mg daily for 5-10 days before a scheduled procedure[7].
  • For immune thrombocytopenia: Starting doses may range from 20-60 mg daily, with adjustments based on platelet response[5].
  • For pediatric patients: Dosing is often based on body weight, with initial doses ranging from 10-40 mg daily[9].

It’s important to note that dosage should always be determined by a healthcare professional and may be adjusted based on individual patient response and platelet counts.

Efficacy and Benefits

Clinical studies have shown several potential benefits of avatrombopag:

  • Increased platelet counts: Many patients experience a significant increase in platelet counts after taking avatrombopag[1][2].
  • Reduced need for platelet transfusions: By increasing platelet production, avatrombopag may reduce the need for platelet transfusions in some patients[1].
  • Improved ability to undergo medical procedures: For patients with chronic liver disease, avatrombopag can help increase platelet counts to safer levels for medical or surgical procedures[7].
  • Potential for long-term management: In conditions like immune thrombocytopenia, avatrombopag may offer a long-term treatment option for maintaining adequate platelet counts[5].

Safety and Side Effects

While avatrombopag is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Fatigue
  • Nausea
  • Abdominal pain

More serious side effects, though rare, can include blood clots due to excessive platelet production. Patients should be monitored regularly while taking avatrombopag, and any unusual symptoms should be reported to a healthcare provider immediately[2][5].

Ongoing Research

Avatrombopag is currently being studied in various clinical trials to explore its potential in treating different conditions and patient populations. Some areas of ongoing research include:

  • Use in severe aplastic anemia patients who have not responded to other treatments[8].
  • Combination therapy with other medications for severe aplastic anemia[1].
  • Treatment of thrombocytopenia in cancer patients undergoing chemotherapy[4].
  • Use in patients with liver cancer (hepatocellular carcinoma) who need to undergo certain procedures[10].

These ongoing studies aim to provide more information about the effectiveness and safety of avatrombopag in various clinical scenarios, potentially expanding its use to benefit more patients in the future.

Aspect Details
Drug Name Avatrombopag (also known as Doptelet)
Drug Class Thrombopoietin receptor agonist (TPO-RA)
Administration Oral tablet, typically 20-60 mg daily
Conditions Studied Severe aplastic anemia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia, thrombocytopenia in liver disease
Primary Outcomes Platelet count increase, overall response rate, safety profile
Secondary Outcomes Time to response, reduction in bleeding events, quality of life improvements
Patient Populations Adults and children with various forms of thrombocytopenia
Notable Trial Designs Single-arm, multicenter, randomized controlled, and observational studies
Potential Benefits Increased platelet counts, reduced need for platelet transfusions, improved quality of life
Safety Monitoring Adverse events, laboratory tests, vital signs, risk of clonal evolution or disease progression

FAQ

  • What is avatrombopag and how does it work? Avatrombopag is an oral medication that mimics the effects of thrombopoietin, a hormone that stimulates platelet production. It works by activating thrombopoietin receptors in the bone marrow, encouraging the body to make more platelets.
  • What conditions is avatrombopag being studied for in clinical trials? Avatrombopag is being studied for various conditions associated with low platelet counts, including severe aplastic anemia, immune thrombocytopenia, chemotherapy-induced thrombocytopenia, and thrombocytopenia in patients with liver disease undergoing medical procedures.
  • How is avatrombopag administered in clinical trials? In most trials, avatrombopag is given as a daily oral tablet. The dosage can vary depending on the condition being treated and the patient's weight, typically ranging from 20 mg to 60 mg per day.
  • What are the primary outcomes being measured in avatrombopag clinical trials? The primary outcomes often include the percentage of patients achieving a specific platelet count threshold, overall response rates, and safety assessments such as the incidence of treatment-emergent adverse events.
  • Are there any notable side effects or safety concerns with avatrombopag? While safety is still being evaluated in clinical trials, some potential side effects may include headache, fatigue, and nausea. Researchers are also monitoring for any risk of blood clots or other serious adverse events. It's important to note that the full safety profile is still being determined through these studies.

Ongoing Clinical Trials on Avatrombopag

  • Study Comparing Avatrombopag and Rituximab for Adults with Immune Thrombocytopenia Not Responding to Corticosteroids

    Recruiting

    1 1 1 1
    Investigated drugs:
    Norway

  • Study on the Effectiveness of Eltrombopag in Combination with Other Drugs for Patients with Immune Thrombocytopenia

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

Glossary

  • Thrombocytopenia: A condition characterized by abnormally low levels of platelets in the blood, which can lead to easy bruising and bleeding.
  • Aplastic Anemia: A rare but serious blood disorder in which the body stops producing enough new blood cells, including platelets, red blood cells, and white blood cells.
  • Immune Thrombocytopenia (ITP): An autoimmune disorder that causes the immune system to mistakenly attack and destroy platelets, leading to a low platelet count.
  • Thrombopoietin Receptor Agonist (TPO-RA): A type of medication that stimulates the production of platelets by activating the thrombopoietin receptor in the bone marrow.
  • Platelet: A type of blood cell that helps form clots to stop bleeding and repair damaged blood vessels.
  • Hematopoietic Stem Cell Transplantation (HSCT): A procedure that replaces damaged or destroyed bone marrow with healthy blood stem cells to restore normal blood cell production.
  • Cyclosporine (CSA): An immunosuppressant medication often used in combination with other treatments for aplastic anemia.
  • Chemotherapy-Induced Thrombocytopenia: A decrease in platelet count caused by the toxic effects of chemotherapy drugs on bone marrow function.
  • Overall Response Rate (ORR): The proportion of patients who have a partial or complete response to treatment in a clinical trial.
  • Common Toxicity Criteria for Adverse Events (CTCAE): A standardized set of criteria for the classification and grading of adverse events in cancer therapy clinical trials and other oncology settings.

References

  1. https://clinicaltrials.gov/study/NCT06254287
  2. https://clinicaltrials.gov/study/NCT04437953
  3. https://clinicaltrials.gov/study/NCT04931849
  4. https://clinicaltrials.gov/study/NCT04609891
  5. https://clinicaltrials.gov/study/NCT04949009
  6. https://clinicaltrials.gov/study/NCT05433922
  7. https://clinicaltrials.gov/study/NCT05087459
  8. https://clinicaltrials.gov/study/NCT05518331
  9. https://clinicaltrials.gov/study/NCT06281327
  10. https://clinicaltrials.gov/study/NCT06001567